IP Library › Granted Patent US 12,188,094
Granted Patent B2
US 12,188,094 · App. 17/216,170 · Granted Jan 7, 2025

Methods of mast cell tumor prognosis and uses thereof

Inventor: Matthew Breen (Apex, NC)
Assignee: North Carolina State University
C12Q1/6886C12Q2537/16C12Q2600/118C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,188,094
App. No.
17/216,170
Granted
Jan 7, 2025
Kind
B2
Abstract

The present disclosure provides methods for detecting a high-risk phenotype of a mast cell tumor (MCT) in a biological sample from a mammal, preferably a dog. Kits, PCR probes and primers to detect high-risk MCT are also provided.

Claims (21)

1. A kit for detecting a high-risk phenotype of a mast cell tumor (MCT) in a biological sample isolated from a dog, the kit comprising nucleic acid probes, primers, or pairs of primers, wherein the nucleic acid probes, primers, or pairs of primers consist of:

first nucleic acid probe, primer, or pair of primers capable of specifically detecting canine chromosomal region CFA 5:38 of CanFam v3 in the biological sample isolated from the dog;

a second nucleic acid probe, primer or pair of primers capable of specifically detecting canine chromosomal region CFA 31:18 of CanFam v3 in the biological sample isolated from the dog;

a third nucleic acid probe, primer or pair of primers capable of specifically detecting canine chromosomal region CFA 20:32 of CanFam v3 in the biological sample isolated from the dog;

a fourth nucleic acid probe, primer or pair of primers capable of specifically detecting canine chromosomal region CFA 20:46 of CanFam v3 in the biological sample isolated from the dog, and

an optional fifth nucleic acid probe, primer or pair of primers capable of specifically detecting a canine chromosomal region other than CFA 5:38, CFA 31:18, CFA 20:32, and CFA 20:46 of CanFam v3 in the biological sample isolated from the dog to serve as a control,

and further wherein the first, second, third, fourth, and the optional fifth nucleic acid probes, primers, or pairs of primers are differentially fluorescently labeled.

2. The kit of claim 1 , wherein the biological sample comprises cancer cells and/or DNA isolated therefrom, optionally wherein the cancer cells are isolated from the bone marrow, skin, lungs, nose, and/or mouth of the dog.

3. The kit of claim 1 , wherein the biological sample is a biopsy.

4. The kit of claim 1 , wherein the biological sample is a cytological smear, a fresh-frozen sample, a fresh sample, a fixed sample, and/or a paraffin-embedded sample.

5. The kit of claim 1 , wherein the kit further comprises one or more additional components selected from the group consisting of blocking agents, detectable labels or labeling agents, and reagents for hybridization of the first, second, third, fourth, and optional fifth nucleic acid probes, primers, or pairs of primers to CFA 5:38, CFA 31:18, CFA 20:32, CFA 20:46, and a canine chromosomal region other than CFA 5:38, CFA 31:18, CFA 20.32, and CFA 20:46, respectively, of CanFam v3 in the biological sample.

6. A kit for detecting a high-risk phenotype of a mast cell tumor (MCT) in a biological sample isolated from a dog, the kit comprising nucleic acid probes, primers, or pairs of primers, wherein the nucleic acid probes, primers, or pairs of primers consist of:

a first nucleic acid probe, primer, or pair of primers capable of specifically detecting canine chromosomal region CFA 5:38 of CanFam v3 in the biological sample isolated from the dog;

a second nucleic acid probe, primer or pair of primers capable of specifically detecting canine chromosomal region CFA 31:18 of CanFam v3 in the biological sample isolated from the dog;

a third nucleic acid probe, primer or pair of primers capable of specifically detecting canine chromosomal region CFA 20:32 of CanFam v3 in the biological sample isolated from the dog;

a fourth nucleic acid probe, primer or pair of primers capable of specifically detecting canine chromosomal region CFA 20:46 of CanFam v3 in the biological sample isolated from the dog, and

an optional fifth nucleic acid probe, primer or pair of primers capable of specifically detecting a canine chromosomal region other than CFA 5:38, CFA 31:18, CFA 20:32, and CFA 20:46 of CanFam v3 in the biological sample isolated from the dog to serve as a control,

and further wherein the first, second, third, fourth, and the optional fifth nucleic acid probes, primers, or pairs of primers are differentially fluorescently labeled and appropriate for use in measuring copy numbers of CFA 5:38, CPA CFA 31:18, CPA CFA 20:32, CPA CFA 20:46, and a canine chromosomal region other than CFA 5:38, CFA 31:18, CFA 20.32, and CFA 20:46 by a technique selected from the group consisting of fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), Serial Analysis of Gene Expression (SAGE), bead-based technologies, single molecule fluorescence in situ hybridization (smFISH) studies, gene expression analysis by massively parallel signature sequencing, next generation sequencing, or droplet digital PCR (ddPCR).

7. The kit of claim 6 , wherein the first, second, third, fourth, and optional fifth nucleic acid probes, primers, or pairs of primers are appropriate for use in measuring copy numbers of CFA 5:38, 31:18, CFA 20:32, CFA 20:46, and a canine chromosomal region other than CFA 5:38, CFA 31:18, CFA 20.32, and CFA 20:46 by droplet digital PCR (ddPCR).

8. The kit of claim 1 , wherein the nucleic acid probes, primers, or pairs of primers consist of a first nucleic acid probe, primer, or pair of primers that is capable of specifically detecting copy number at CFA 5:38: a second nucleic acid probe, primer, or pair of primers that is capable of specifically detecting copy number at CPA 31:18; a third nucleic acid probe, primer, or pair of primers that is capable of specifically detecting copy number at CPA 20:32; a fourth nucleic acid probe, primer, or pair of primers that is capable of specifically detecting copy number at CFA 20:46; and a fifth nucleic acid probe, primer, or pair of primers that is capable of specifically detecting copy number at a canine chromosomal region other than CFA 5:38, CFA 31:18, CFA 20.32, and CFA 20:46.

9. The kit of claim 1 , wherein the kit further comprises instructions for use of the kit in measuring copy numbers of CFA 5:38, CFA 31:18, CFA 20:32, CFA 20:46 of CanFam v3, and optionally a dog chromosome other than CFA 5, CFA 20, or CFA 31 in the biological sample.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2021
From: BREEN, MATTHEW
To: NORTH CAROLINA STATE UNIVERSITY
Reel/Frame 057045/0546 →
Continuity (3)
Division 16305315
Provisional Application 62343503 · May 31, 2016
Related Publication 20210238695A1 · Aug 5, 2021
References Cited (138)
US 6905823B2 · Kallioniemi et al. · 2005 [cited by applicant]
US 7930104B2 · Baker et al. · 2011 [cited by applicant]
US 7960110B2 · Bastian et al. · 2011 [cited by applicant]
US 9090945B2 · Breen · 2015 [cited by applicant]
US 9290814B2 · Giafis et al. · 2016 [cited by applicant]
US 10501806B2 · Breen · 2019 [cited by applicant]
US 10513738B2 · Breen · 2019 [cited by applicant]
US 10961591B2 · Breen · 2021 [cited by applicant]
US 20070275403A1 · Morrison et al. · 2007 [cited by applicant]
US 20090155805A1 · Zhang et al. · 2009 [cited by applicant]
US 20090299640A1 · Ellis et al. · 2009 [cited by applicant]
US 20090324596A1 · Kang et al. · 2009 [cited by applicant]
US 20130210014A1 · Sharman · 2013 [cited by applicant]
US 20160289767A1 · Breen · 2016 [cited by applicant]
US 20170037481A1 · Breen · 2017 [cited by applicant]
US 20170211150A1 · Breen · 2017 [cited by applicant]
US 20190185943A1 · Breen · 2019 [cited by applicant]
US 20200109457A1 · Breen · 2020 [cited by applicant]
US 20200181719A1 · Breen · 2020 [cited by applicant]
US 20210238695A1 · Breen · 2021 [cited by applicant]
EP 2513340B1 · 2016 [cited by applicant]
WO WO2002077197 · 2002 [cited by applicant]
WO WO2002100246 · 2002 [cited by applicant]
WO WO2009051842 · 2009 [cited by applicant]
WO WO2012078053 · 2012 [cited by applicant]
WO WO2012135125 · 2012 [cited by applicant]
WO WO2017210115 · 2017 [cited by applicant]
Thomas et al. (J. of Heredity, Am. Genetic Association, vol. 98, No. 5, pp. 474-484, 2007). (Year: 2007). [cited by examiner]
Hedan et al. (BMC Cancer, vol. 11, pp. 1-14, May 26, 2011). (Year: 2011). [cited by examiner]
Milne et al. (Chromosome Research, vol. 12, pp. 825-835, 2004). (Year: 2004). [cited by examiner]
Jark et al. (Research in Veterinary Science, vol. 111, pp. 26-30, Epublished Nov. 17, 2016). (Year: 2016). [cited by examiner]
Mochizuki et al. (Chromosome Res vol. 25, pp. 129-143, published online Jan. 5, 2017). (Year: 2017). [cited by examiner]
Al Mulla et al., “Genetic profiling of stage I and II colorectal cancer may predict metastatic relapse,” Modern Pathology. vol. 19, No. 5 pp. 648-658 (2006). [cited by applicant]
Angstadt et al., “Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signature of genomic imbalance in canine osteosarcoma parallel the human counterpart.” Genes Chromosomes … [cited by applicant]
Angstadt, Andrea Y. et al.; “A genome-wide approach to comparative oncology: high-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations,” Cancer Genetics, 2012. [cited by applicant]
Arendt et al., “Genome-Wide Association Study of Golden Retrievers Identifies Germ-Line Risk Factors Predisposing to Mast Cell Tumours.” PLoS Genet, vol. 11, Article ID e1005647 (2015). [cited by applicant]
Bowman et al. (Molecular Evaluation of Canine Urothelial Carcinoma and the Cell line Model, NCSU CVM Annual Research Forum Award of Excellence for Poster presentation, Feb. 2013). (Year: 2013). [cited by applicant]
Breen et al. “An integrated 4249 marker FISH/RH map of the canine genome.” BMC Genomics 5(1):65 (2004). [cited by applicant]
Breen et al. “Chromosome-Specific Single-Locus FISH Probes Allow Anchorage of an 1800-Marker Integrated Radiation-Hybrid/Linkage Map of the Domestic Dog Genome to All Chromosomes”, Genome Research, 11:784-1795 (2001). [cited by applicant]
Breen, “Update on genomics in veterinary oncology.” Top Companion Anim Med, vol. 24, pp. 113-121 (2009). [cited by applicant]
Breen, M., “Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans—man and his best friend share more than companionship,” vol. 16, No. 1, pp. 145-154 (Feb. 25, 2008). [cited by applicant]
Brown, Subtelomeric chromosome rearrangements are detected using an innovative 12-color FISH assay (M-TEL), Nature Medicine, vol. 7, No. 4, pp. 497-501 (2001). [cited by applicant]
Choi, et al., “Color Compensation of Multicolor FISH Images”, IEEE Transactions on Medical Imaging, vol. 28, No. 1, pp. 129-136 (2009). [cited by applicant]
Decision to grant a European patent pursuant to Article 97(1) EPC for European Patent Application No. 10861217.7 dated Jun. 2, 2016. [cited by applicant]
Decision to Grant corresponding to European U.S. Appl. No. 14/861,374 dated Dec. 10, 2020. [cited by applicant]
European Search Report corresponding to European Patent Application No. 10861217.7-1403/2513340 dated Jun. 3, 2013. [cited by applicant]
European Search Report corresponding to European Patent Application No. 17807289.8 dated Jan. 10, 2020. [cited by applicant]
Extended European Search Report issued in counterpart European Application No. 14861374.8 dated May 29, 2017 eleven (11) pages). [cited by applicant]
Giantin et al., “Global gene expression analysis of canine cutaneous mast cell tumor: could molecular profiling be useful for subtype classification and prognostication?” PLoS One, vol. 9, Article ID e95481 (2014). [cited by applicant]
Haenisch et al., “Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis heritability and diagnostics.” Immunology, vol. 137, pp. 197-205 (2012). [cited by applicant]
Hahn et al., “Diagnostic and Prognostic Importance of Chromosomal Aberrations Identified in 61 Dogs with Lymphosarcoma,” Veterinary Pathology, vol. 31, No. 5, pp. 528-540 (Sep. 1, 1994). [cited by applicant]
Hedan et al. (2011) Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of geneti… [cited by applicant]
Intention to Grant corresponding to European Patent Application No. 14861374.8 dated Jan. 7, 2020. [cited by applicant]
International Preliminary Report dated Feb. 2, 2017 from related International Application No. PCT/US2015/41988. [cited by applicant]
International Preliminary Report on Patentability for related PCT Application No. PCT/US2014/065773 dated May 17, 2016. [cited by applicant]
International search report and the written opinion of the international searching authority for a related PCT Application No. PCT/US2014/065773 dated May 21, 2015. [cited by applicant]
International Search Report and Written Opinion dated Jul. 2, 2015 from related International Application No. PCT/US2015/025916. [cited by applicant]
International Search Report and Written Opinion dated Oct. 30, 2015 from related International Application No. PCT/US2015/41988. [cited by applicant]
International Search Report and Written Opinion issued in PCT Application No. PCT/US2017/034711 dated Sep. 14, 2017 (six (6) pages). [cited by applicant]
Johnson et al., “Chemotherapy for Dogs with Mast Cell Tumors Approved by the FDA,” Advances in Small Animal Medicine and Surgery, vol. 23., No. 1 (2010). [cited by applicant]
Karlin-Neumann al. (2012). Probing copy number variations using Bio-Rad's QX100™ Droplet Digital™ PCR system. Bio-Rad Bulletin 6277. [cited by applicant]
Kennedy et al., “Genome-wide DNA copy number analysis and targeted transcriptional analysis of canine histiocytic malignancies identifies diagnostic signatures and highlights disruptions of spindle assembly complex,” Ch… [cited by applicant]
Koenig, A.; “Expression and Significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN Tumor Suppressors in Canine Melanoma,” Vet Pathol. 39: 458-472 (2002). [cited by applicant]
Letard et al.,(2008) “Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors.” Mol Cancer Res, vol. 6, pp. 10 Pages. [cited by applicant]
Lin et al., “Generation and characterization of novel canine malignant mast cell line CL1.” Vet Immunol Immunopathol, vol. 127, pp. 114-124 (2009). [cited by applicant]
Lin Tzu-Yin et al., “Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand”, Molecular Cancer, Biomed Central, London, GB, vol. 10, No. 1, Jan. 27, 2011 ( Jan. 27, 2011), age 9… [cited by applicant]
Magdy Sayed Aly et al: “Chromosomal aberrations in early-stage bilharzia! bladder cancer”, Cancer Genetics and Cytogenetics., vol. 132, No. 1, Jan. 1, 2002 (Jan. 1, 2002), pp. 41-45, XP055372968, us SSN: 0165-4608, DOI:… [cited by applicant]
Maria I. Stamouli et al: “Detection of genetic alterations in primary bladder carcinoma with dual-color and multiplex ftuorescence in situ hybridization”, Cancer Genetics and Cytogenetics., vol. 149, No. 2, Mar. 1, 004 … [cited by applicant]
Marin-Aguilera Mercedes et al: “Utility of Fluorescence in Situ Hybridization as a Non-invasive Technique in he Diagnosis of Upper Urinary Tract Urothelial Carcinoma”, European Urology, vol. 51, No. 2, Aug. 22, 2006Aug.… [cited by applicant]
Milne et al., “Karyotype of canine soft tissue sarcomas: a multi-colour, multi-species approach to canine chromosome painting”, Chromosome Research, vol. 12 pp. 825-835 (2004). [cited by applicant]
Mochizuki et al., “Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction.” Vet Pathol, vol. Nov. 2015 (2015). [cited by applicant]
Modiano et al., “Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma,” Leukemia. vol. 21, No. 1 pp. 184-187 (2007). [cited by applicant]
Muller et al. (2012) Genetic characterization via array based comparative genomic hybridization. Tierarztliche Praxis. 40(1):55-58. [cited by applicant]
Mullins et al. “Agreement in Breast Cancer Classification between Microarray and Quantitative Reverse Transcription PCR from Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Tissues” Clin Chem. 53(7): 1273-1279 (2007). [cited by applicant]
Notice of Acceptance corresponding to Australian Patent Application No. 2014348428 dated Dec. 7, 2020. [cited by applicant]
Notice of Allowability corresponding to U.S. Appl. No. 15/037,438 dated Jul. 31, 2019. [cited by applicant]
Notice of Allowance corresponding to Canadian Patent Application No. 2,785,999 dated Nov. 10, 2020. [cited by applicant]
Notice of Allowance corresponding to Japanese Patent Application No. 2016-554527 dated Feb. 5, 2019. [cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 15/037,438 dated Jun. 7, 2019. [cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 15/328,733 dated Jul. 16, 2019. [cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 15/304,388 dated Jul. 24, 2019. [cited by applicant]
Notice of Publication corresponding to U.S. Appl. No. 16/659,095 dated Apr. 9, 2020. [cited by applicant]
Notice of Publication corresponding to U.S. Appl. No. 16/707,745 dated Jun. 11, 2020. [cited by applicant]
Notice of Publication corresponding to U.S. Appl. No. 16/725,195 dated Jul. 31, 2020. [cited by applicant]
Notice of Publication Corresponding to U.S. Appl. No. 17/216,170 dated Aug. 6, 2021. [cited by applicant]
Notification Concerning Transmittal of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) corresponding to International Patent Application No. PCT/US2010/060292 dated Aug. 30… [cited by applicant]
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration corresponding to International Patent Application No. PCT/US2010/060292… [cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 15/328,733 dated Apr. 27, 2018. [cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 15/328,733 dated Feb. 15, 2019. [cited by applicant]
Office Action corresponding to Canadian Patent Application No. 2,785,999 dated Aug. 16, 2016. [cited by applicant]
Office Action corresponding to Japanese Patent Application No. 2016-554527 dated Sep. 25, 2018. (Translation). [cited by applicant]
Office Action corresponding to U.S. Appl. No. 13/515,614 dated Jul. 30, 2014. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 15/037,438 dated Aug. 15, 2017. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 15/037,438 dated May 23, 2018. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 15/037,438 dated Jan. 8, 2019. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 15/037,438 dated Nov. 24, 2017. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/725,195 dated Apr. 5, 2022. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/707,745 dated May 2, 2022. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/659,095 dated Aug. 11, 2022. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/725,195 date Nov. 7, 2022. [cited by applicant]
Office Action corresponding with European Patent Application No. 10861217.7-1403 dated Apr. 25, 2014. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/707,745 dated Dec. 3, 2021. [cited by applicant]
Office Action corresponding with European Patent Application No. 14861374.8-1118 dated Apr. 4, 2019. [cited by applicant]
Oral Summons corresponding with European Patent Application No. 10861217.7-1403 dated Jun. 12, 2015. [cited by applicant]
Ratcliffe et al., “Proteomic identification and profiling of canine lymphoma patients,” Veterinary and Comparative Oncology. vol. 7, No. 2 pp. 92-105 (2009). [cited by applicant]
Roode et al., “Genome-wide assessment of recurrent genomic imbalances in canine leukemia identifies evolutionarily conserved regions for subtype differentiations,” Chromosome Research, Kluwer Academic Publishers, vol. 2… [cited by applicant]
Roode, Sarah Culvar.; “Molecular Characterization of Canine Leukemia—Comparative Value and Clinical Applications,” A dissertation submitted to the Graduate Faculty of North Carolina State University in partial fulfillme… [cited by applicant]
Sailasuta, A. et al. “The Relevance of CD117-Immunocythochemistry Staining Patterns to Mutational Exon-11 in c-kit Detected by PCR from Fine-Needle Aspirated Canine Mast Cell Tumor Cells” Veterinary Medicine Internation… [cited by applicant]
Seiser et al. “Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines.” Veterinary and comparative oncology 11(1): 30-50 (2013). [cited by applicant]
Sotirakopolous et al.: “Evaluation of Microsatellite Instability in Urine for the Diagnosis of Transitional Cell Carcinoma of the Lower Urinary Tract in Dogs”, J Vet Med, 24: 1445-1451 (2010). [cited by applicant]
Supplementary material for Thomas R, et al.; “Refining tumor-associated aneuploidy through ‘genomic recoding’ of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas,” Leukemia & Lymphoma, 2011. [cited by applicant]
Thomas et al. (2009) “Influence of genetic background on tumor karyotypes: evidence for breed-associated cytogenetic aberrations in canine appendicular osteosarcoma,” Chromosome Research, vol. 10, 20 Pages. [cited by applicant]
Thomas et al., “A canine cancer-gene microarray for CGH analysis of tumors,” Cytogenetic and Genome Research, vol. 102, No. 1-4, pp. 254-260 (2003). [cited by applicant]
Thomas et al., “A Cytogenetically Characterized, Genome-Anchored 10-M b BAC Set and CGH Array for the Domestic Dog”, Journal of Heredity., vol. 98, No. 5, Jul. 23, 2007 (Jul. 23, 2007), pp. 474-484, XP055343142,3B ISSN:… [cited by applicant]
Thomas et al., “Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes,” British Journal of Cancer. vol. 89, No. 8 pp. 1530-1537 (2003). [cited by applicant]
Thomas, Chromosome Res, vol. 22, No. 3, pp. 305-319, 2017 (Year: 2014). [cited by applicant]
Thomas, R., et al. “A genome assembly-integrated dog 1 Mb BAC microarray: a cytogenetic resource for canine cancer studies and comparative genomic analysis.” Cytogenetic and genome research 122(2): 110-121 (2008). [cited by applicant]
Thomas, Rachael et al., “Construction of a 2-Mb resolution BAG microarray for CGH analysis of canine tumors,” Genome Research, pp. 1832-1837, Dated Feb. 13, 2005, Revised May 4, 2005. [cited by applicant]
Urovysion Bladder Cancer Kit; < http://www.abbottmolecular.com> Accessed Nov. 11, 2013. [cited by applicant]
Urovysion Bladder Cancer Kit; Package Insert; Abbott Laboratories, 2006. [cited by applicant]
Winkler et al. (2006) Polysomy 13 in a canine prostate carcinoma underlining its significance in the development of prostate cancer. Cancer Genet. Cytogenet. 169:154-158. [cited by applicant]
Letard S. et al. “Gain-of-Function Mutations in the Extracellular Domain of KIT Are Common in Canine Mast Cell Tumors” Molecular Cancer Research. 2008 pp. 1137-1145 {ten (10) pages). [cited by applicant]
Lin et al. (Veterinary Immunology and Immunopathology, vol. 127, pp. 114-124, 2009) (Year: 2009). [cited by applicant]
Mochizuki, A. et al. “Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction” Oncology-Original Article. Veterinary Pathology_ 2016, vol. 53(4) pp. 764-772 (nine… [cited by applicant]
Notice of Acceptance corresponding to Australian Patent Application No. 2014348248 dated Dec. 7, 2020. [cited by applicant]
Notice of Allowance corresponding to Canadian Patent Application No. 2,785,999 dated Dec. 8, 2020. [cited by applicant]
Thomas et al. (Chromosome Research, vol. 10, Apr. 1, 2009 (Year: 2009). [cited by applicant]
Thomas, Rachael, et al. “Refining tumor-associated aneuploidy through ‘genomic receding’ of recurrent DNA copy umber aberrations in 150 canine non-Hodgkin lymphomas.” Leukemia & lymphoma 52(7): 1321-1335 (2011). [cited by applicant]
Intention to Grant (2nd) corresponding to European Patent Application No. 14861374.8 dated Jun. 18, 2020. [cited by applicant]
Intention to Grant corresponding to European Patent Application No. 17807289.8 dated Jan. 7, 2020. [cited by applicant]
Mutsaers, A.J., W.R. Widmer, and D.W. Knapp, Canine transitional cell carcinoma. J Vet Intern Med, 2003. 17(2): p. 136-44. [cited by applicant]
Notice of Allowance corresponding to U.S. Appl. No. 16/305,315 dated Nov. 18, 2020. [cited by applicant]
Office Action (Restriction Requirement) corresponding to U.S. Appl. No. 16/305,315 dated Jun. 15, 2020. [cited by applicant]
Office Action corresponding to Canadian Patent Application No. 3,025,776 dated Mar. 31, 2023. [cited by applicant]
Office Action and Interview Summary corresponding to U.S. Appl. No. 16/659,095 dated Apr. 28, 2023. [cited by applicant]
Office Action corresponding to U.S. Appl. No. 16/725,195 dated Jan. 23, 2024. [cited by applicant]
Office Action and Interview Summary corresponding to U.S. Appl. No. 16/659,095 dated May 24, 2024. [cited by applicant]
Supplemental Notice of Allowability corresponding to U.S. Appl. No. 16/305,315 dated Dec. 31, 2020. [cited by applicant]